Verici Dx plc (AIM:VRCI)

Market Cap	10.22M +12.3%
Revenue (ttm)	1.40M -55.9%
Net Income	-5.56M
EPS	-0.02
Shares Out	1.51B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,164,625
Average Volume	1,696,399
Open	0.6700
Previous Close	0.6750
Day's Range	0.6500 - 0.7000
52-Week Range	0.4660 - 3.7500
Beta	1.58
RSI	12.51
Earnings Date	Apr 14, 2026

About Verici Dx

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functiona...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 15
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.

Financial numbers in USD